Tools for Practice Outils pour la pratique


#193 Riboflavin for Migraine Prophylaxis: Something “2-B” excited about?


CLINICAL QUESTION
QUESTION CLINIQUE
Does daily riboflavin (vitamin B2) prevent migraines?


BOTTOM LINE
RÉSULTAT FINAL
Studies of riboflavin are inconsistent and often have high placebo response rates. Most randomized, controlled trials (RCTs) found no reduction in migraine frequency. One study found for every three adults treated with riboflavin, one patient would have a ≥ 50% reduction in migraine frequency compared to placebo. Adverse effects are poorly reported, but include diarrhea and discoloured urine.  



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Adults:  
  • Three double-blind randomized controlled trials (RCTs), younger, predominantly female, Western Europe/US. All outcomes reported at three months.  
    • 55 patients, ~4 migraines/month, randomized to riboflavin 400 mg daily or placebo (with ß-carotene).1  
      • ≥ 50% reduction in frequency: 56% versus 19% (placebo); Number Needed to Treat (NNT)=3. 
      • Limitations: Inconsistent statistical applications, origin of funding unclear, limited adverse event reporting. 
    • 112 patients, six days of migraine/month, randomized to nutritional product with riboflavin 400 mgMagnesium/Coenzyme Q10 and other vitamins or indistinguishable placebo divided twice daily.2   
      • Both reduced days of migraine/month 1.8 versus 1.3 (placebo). Not statistically significant (NSS). 
        • No meaningful differences in other outcomes. 
      • More adverse effects with riboflavin (mostly diarrhea or discoloured urine): Number Needed to Harm (NNH)=4. 
      • Limitations: Unclear randomization concealment (with more in placebo having co-morbidities). 
    • 49 patientsRiboflavin 400 mg with magnesium/feverfew or placebo (riboflavin 25 mg).3   
      • 50% reduction in frequency 42% versus 44(placebo); NSS. 
      • Fewer monthly migraines: 1.8 versus 1.7 (placebo); NSS. 
      • Limitations: Unclear randomization concealment, possible active comparator, no adverse effects reported. 
Pediatrics: 
  • Two placebo-controlled RCTs (Australia/Netherlands) riboflavin 50 mg versus placebo (with carotene) (42 children)4 and 200 mg versus identical placebo (48 children):5   
    • No difference in days with migraine or headache intensity.4,5 
    • 50% reduction in frequency: 44% versus 67% (placebo); NSS.5  
    • Limitations: Underpowered5 
  • Third study uninterpretable due to significant differences in baseline characteristics.6 
  • Systematic reviews did not complete meta-analyses (so we focused on RCTs above).7-10 
Context: 
  • Prophylaxis is recommended for those with ≥3 moderate-severe headaches/month.7 
    • The best evidence for migraine prophylaxis supports propranolol and amitriptyline, which benefit 1 in 4 and 1 in 8 patients over placebo, respectively.11,12   
  • Guidelines “strongly recommend” riboflavin (based on low quality evidence)7 or suggest riboflavin probably effective8 in adults.


Latest Tools for Practice
Derniers outils pour la pratique

#359 Topical corticosteroids for atopic dermatitis - More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?
Read Lire 0.25 credits available Crédits disponibles

#358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?
Read Lire 0.25 credits available Crédits disponibles

#357: Overcoming Resistance: Antipsychotics for difficult to treat depression

In patients with treatment-resistant depression, is adding an atypical antipsychotic to current therapy safe and effective?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Evan Sehn BScPharm PharmD Candidate
  • Michael R Kolber BSc MD CCFP MSc
  • Adrienne J Lindblad BSP ACPR PharmD

1. Schoenen J, Jacquy J, Lenaerts M. Neurology. 1998; 50(2):466-70.

2. Gaul C, Diener H-C, Danesch U. J Headache Pain. 2015; 16(32):1-8.

3. Maizels M, Blumenfeld A, Burchette R. Headache. 2004; 44(9):885-90.

4. Bruijn J, Duivenvoorden H, Passchier J, et al. Cephalalgia. 2010; 30(12):1426-34.

5. MacLennan S, Wade F, Forrest KM, et al. J Child Neurol. 2008; 23(11):1300-4.

6. Athaillah, Dimyati Y, Saing JH, et al. Paediatr Indones. 2012; 52(3):132-7.

7. Pringsheim T, Davenport WJ, Mackie G, et al. Can J Neurol Sci. 2012; 39(2):Supplement 2.

8. Holland S, Silberstein SD, Freitag F, et al. Neurology. 2012; 78:1346-53.

9. Orr SL, Venkateswaran S. Cephalalgia. 2014; 34(8):568-83.

10. Namazi N, Heshmati J, Tarighat-Esfanjani A. Int J Vitam Nutr Res. 2015; 85(1-2):79-87.

11. Kapusta MJ, Allan GMA. Tools for Practice. Available at: https://www.acfp.ca/wp-content/uploads/tools-for-practice/1433184708_updatedtfp52antihypertensivesmigraineprophylaxis.pdf. Last Accessed: March 22, 2017.

12. Allan GMA, Levy M. Tools for Practice. Available at: https://www.acfp.ca/wp-content/uploads/tools-for-practice/1433184684_updatedtfp51antidepressantsheadaches.pdf. Last Accessed: March 22, 2017.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.